Guidelines suggest observation stays are appropriate for pulmonary embolism (PE) patients at low risk for early mortality. The investigators sought to asses agreement between United States (US) observation management of PE and claims-based clinical risk stratification criteria.
Thrombosis is the common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused 1 in 4 deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability.
Chronic thromboembolic pulmonary hypertension (CTPH) is associated with considerable morbidity and mortality. Its incidence after pulmonary embolism and associated risk factors are not well documented.
Pulmonary embolism (PE) is a common and potentially fatal form of venous thromboembolism (VTE) that can be challenging to diagnose and manage. PE occurs when there is obstruction of the pulmonary vasculature and is a common cause of morbidity and mortality in the United States.
Studies on long-term mortality after venous thromboembolism (VTE) are sparse. Using Danish medical databases, a 30-year nationwide population-based cohort study was conducted of 128,223 patients with first-time VTE (1980–2011) and a comparison cohort of 640,760 people from the general population (without VTE) randomly matched by sex, year of birth, and calendar period.
The Pulmonary Embolism Severity Index (PESI) estimates the risk of 30-day mortality in patients with acute pulmonary embolism (PE). We constructed a simplified version of the PESI.
This article studies the safety of outpatient treatment in low risk patients with acute pulmonary embolism compared with inpatient treatment, the current clinical standard.
Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with significant morbidity and mortality. VTE frequently leads to hospitalization and represents a considerable economic burden to the US health care system. However, little information exists on the duration of hospitalization and associated charges among patients with an admitting or primary diagnosis of DVT or PE. This study assessed the charges associated with hospitalization length of stay in patients with DVT or PE discharged from US hospitals in 2011.
Pulmonary embolism (PE) is responsible for 300,000 US deaths each year. Initial PE-related hospitalization costs were estimated at $13,300-$31,000 annually.
Various risk stratification methods exist for patients with pulmonary embolism (PE). Use the simplified Pulmonary Embolism Severity Index (sPESI) as a risk stratification method to understand the PE population within the Veterans Health Administration (VHA).
Clinical guidelines recommend early discharge of patients with low-risk pulmonary embolism (LRPE). This study measured the overall impact of early discharge of LRPE patients on clinical outcomes and costs in the Veterans Health Administration population.
Venous thromboembolism (VTE) is a common medical condition manifested as deep vein thrombosis (DVT) or pulmonary embolism (PE). Few data exist on the total economic burden of DVT and PE.
Thrombolytic therapy may be beneficial in the treatment of some patients with pulmonary embolism. To date, no analysis has had adequate statistical power to determine whether thrombolytic therapy is associated with improved survival, compared with conventional anticoagulation.
Patients with acute deep vein thrombus (DVT) can safely be treated as outpatients. However the role of outpatient treatment in patients diagnosed with a pulmonary embolism (PE) is controversial. The authors sought to determine the safety of outpatient management of patients with acute symptomatic PE.
Our vision is to improve the lives of the millions of people with cardiovascular disease and diabetes, and to work tirelessly to eliminate these diseases. Every year 19 million people around the world die from cardiovascular and metabolic diseases. This tremendous global burden compels us to develop new therapies that will change the face of these diseases and, ultimately, eliminate them. We focus on finding and developing truly transformational therapies that target underlying disease pathways, important pathways, and novel mechanisms of action. We have a very successful track record demonstrated by the development and recent successful launches of our products for the treatment of patients suffering from thrombosis and type 2 diabetes. And we continue to seek and develop the next generation of transformational cardiovascular and metabolic therapies.
Focusing on the Most Devastating Diseases of Our Lifetime
We want to drive down the rates of cardiovascular and metabolic diseases with our science, innovation, and solutions. We are already transforming the treatment of type 2 diabetes and thrombosis with our products. And while these important products continue to change the way doctors are treating diabetes and thrombosis, we are also focused on finding the next wave of transformational treatments for cardiovascular and metabolic diseases that will prevent, intercept, and cure devastating diseases.